Polycystic ovary syndrome (PCOS) usually arises during puberty and is marked by hyperinsulinemia and hyperandrogenism. Adolescents with PCOS are at an increased risk of developing health problems later on in life such as type 2 diabetes, cardiovascular disease, and infertility. Furthermore, the physical signs of PCOS can be detrimental to a teenage girl's self-image. Early diagnosis and treatment of PCOS in adolescents are essential in ensuring adulthood health and restoring self-esteem. Treatments for an adolescent with PCOS include diet and exercise, metformin, and oral contraceptive pills. Each of these options has been shown to be effective in improving certain aspects of PCOS, and probably the best treatment plan involves some combination of them.
KovacsG, SmithJ.A Guide to the Polycystic Ovary: Its effects on health and fertility. Castle Hill Barns, UK: TFM Publishing, 2002.
2.
AchardC, ThiersJ.Le virilisme pilaire et son association à l'insuffisance glycolytique (diabète des femme à barbe). Bull Acad Natl Med86:51–83, 1921.
3.
SteinIF, LeventhalML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol29:181–191, 1935.
4.
BattagliaC, RegnaniG, ManciniF, IughettiL, FlamigniC, VenturoliS.Polycystic ovaries in childhood: a common finding in daughters of PCOS patients. A pilot study. Hum Reprod17:771–776, 2002.
5.
JahanfarS, EdenJA, WarrenP, SeppalaM, NguyenTV. A twin study of polycystic ovary syndrome. Fertil Steril63:478–486, 1995.
6.
LegroRS, DriscollD, StraussJFIII, FoxJ, DunaifA.Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A95:14956–14960, 1998.
7.
YildizBO, YaraliH, OguzH, BayraktarM.Glucose intolerance, insulin resistance, and hyperandrogenism in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab88:2031–2036, 2003.
8.
BridgesNA, CookeA, HealyMJ, HindmarshPC, BrookCG. Standards for ovarian volume in childhood and puberty. Fertil Steril60:456–460, 1993.
HolteJ.Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style?J Endocrinol Invest21:589–601, 1998.
11.
RajkhowaM, TalbotJA, JonesPW, ClaytonRN. Polymorphism of glycogen synthetase gene in polycystic ovary syndrome. Clin Endocrinol44:85–90, 1996.
12.
WitchelSF, TrivediRN, KammererC.Frequency of the T228A polymorphism in the SORBS1 gene in children with premature pubarche and in adolescent girls with hyperandrogenism. Fertil Steril80:128–132, 2003.
13.
TombocM, WitchelSF. Frequencies of the D85 and Y85 variants of UGT2B15 in children and adolescent girls with hyperandrogenism. J Pediatr Endocrinol Metab16:719–726, 2003.
14.
TapanainenJS, KoivunenR, FauserBC, TaylorAE, ClaytonRN, RajkowaM, WhiteD, FranksS, AntillaL, PetterssonKS, HuhtaniemiIT. A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. J Clin Endocrinol Metab84:1711–1715, 1999.
15.
SiegelS, FutterweitW, DaviesTF, ConcepcionES, GreenbergDA, VillanuevaR, TomerY.A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril78:1240–1243, 2002.
WoodJR, NelsonVL, HoC, JansenE, WangCY, UrbanekM, McAllisterJM, MosselmanS, StraussJFIII. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem278:26380–26390, 2003.
19.
NobelsF, DewaillyD.Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis. Fertil Steril58:655–666, 1992.
20.
CarminaE, LoboRA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab84:1897–1899, 1999.
21.
MeirowD, SchenkerJG. The link between female infertility and cancer: epidemiology and possible aetiologies. Hum Reprod Update2:63–75, 1996.
22.
SchildkrautJM, SchwinglPJ, BastosE, EvanoffA, HughesC.Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88(4, Pt 1):554–559, 1996.
23.
OvalleF, AzzizR.Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril77:1095–1105, 2002.
24.
KidsonW.Polycystic ovary syndrome: a new direction in treatment. Med J Aust169:537–540, 1998.
25.
LegroRS, KunselmanAR, DodsonWC, DunaifA.Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab84:165–169, 1999.
26.
LewyVD, DanadianK, WitchelSF, ArslanianS.Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr138:38–44, 2001.
27.
ArslanianSA, LewySD, DanadianK.Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab86:66–71, 2001.
28.
RajkhowaM, NearyRH, KumpatlaP, GameFL, JonesPW, ObhraiMS, ClaytonRN. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab82:3389–3394, 1997.
29.
ChristianRC, DumesicDA, BehrenbeckT, ObergAL, SheedyPF, FitzpatrickLA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab88:2562–2568, 2003.
30.
TalbottE, GuzickD, ClericiA, BergaS, DetreK, WeimerK, KullerL.Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol15:821–826, 1995.
31.
MacutD, MicicD, CvijovicG, SumaracM, KendereskiA, ZoricS, PejkovicD.Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 14(Suppl 5): 1353–1359 (discussion, 1365), 2001.
32.
TrentME, RichM, AustinSB, GordonCM. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med156:556–560, 2002.
33.
RasgonNL, RaoRC, HwangS, AltshulerLL, ElmanS, Zuckerbrow-MillerJ, KorenmanSG. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord74:299–304, 2003.
34.
BarthJH, CatalanJ, CherryCA, DayA.Psychological morbidity in women referred for treatment of hirsutism. J Psychosom Res37:615–619, 1993.
35.
SoninoN, FavaGA, ManiE, BelluardoP, BoscaroM.Quality of life of hirsute women. Postgrad Med J 69(809): 186–189, 1993.
36.
KitzingerC, WillmottJ.“The thief of womanhood”: women's experience of polycystic ovarian syndrome. Soc Sci Med54:349–361, 2002.
37.
TrentME, RichM, AustinSB, GordonCM. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. J Pediatr Adolesc Gynecol16:33–37, 2003.
ZawadzkiJK, DunaifA.Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: DunaifA, GivensJR, HaseltineF, MerriamGR, Eds. Polycystic Ovary Syndrome. Boston: Blackwell, pp377–384, 1992.
40.
LewisV.Polycystic ovary syndrome: a diagnostic challenge. Obstet Gynecol Clin North Am28:1–20, 2001.
41.
ApterD, BützowT, LaughlinGA, YenSSC. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab80:2966–2973, 1995.
42.
KentSC, LegroRS. Polycystic ovary syndrome in adolescents. Adolesc Med13:73–88, 2002.
43.
HerterLD, MagalhaesJA, SpritzerPM. Relevance of the determination of ovarian volume in adolescent girls with menstrual disorders. L Clin Ultrasound24:243–248, 1996.
44.
DramusicV, GohVH, RajanU, WongYC, RatnamSS. Clinical, endocrinologic, and ultrasonographic features of polycystic ovary syndrome in Singaporean adolescents. J Pediatr Adolesc Gynecol10:124–132, 1997.
45.
FulghesuAM, CiampelliM, BelosiC, ApaR, PavoneV, LanzoneA.A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril76:326–331, 2001.
RichardsGE, CavalloA, MeyerWJIII, PrinceMJ, PetersEJ, StuartCA, SmithER. Obesity, acanthosis nigricans, insulin resistance, and hyperandrogenemia: pediatric perspective and natural history. J Pediatr107:893–897, 1985.
48.
DeClueTJ, ShahSC, MarcheseM, MaloneJI. Insulin resistance and hyperinsulinemia induce hyperandrogenism in a young type B insulin-resistant female. J Clin Endocrinol Metab72:1308–1311, 1991.
49.
BiloL, MeoR, ValentinoR, Di CarloC, StrianoS, NappiC.Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab86:2950–2956, 2001.
50.
MeoR, BiloL.Polycystic ovary syndrome and epilepsy: a review of the evidence. Drugs63:1185–1227, 2003.
51.
TaponenS, MartikainenH, JarvelinMR, LaitinenJ, PoutaA, HartikainenAL, SovioU, McCarthyMI, FranksS, RuokonenA.Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab88:141–147, 2003.
52.
BiliH, LavenJ, ImaniB, EijkemansMJ, FauserBC. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years. Eur J Endocrinol145:749–755, 2001.
53.
GulekliB, TurhanNO, SenozS, KuknerS, OralH, GokmenO.Endocrinological, ultrasonographic and clinical findings in adolescent and adult polycystic ovary patients: a comparative study. Gynecol Endocrinol7:273–277, 1993.
54.
VetrM, SobekA.Low dose spironolactone in the treatment of female hyperandrogenism and hirsutism. Acta Univ Palacki Olomuc Fac Med135:55–57, 1993.
55.
De LeoV, LanzettaD, D'AntonaD, la MarcaA, MorganteG.Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab83:99–102, 1998.
56.
JensenJT, SperoffL.Health benefits of oral contraceptives. Obstet Gynecol Clin North Am27:705–721, 2000.
57.
CreatsasG, KoliopoulosC, MastorakosG.Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci900:245–252, 2000.
58.
LloydT, LinHM, MatthewsAE, BentleyCM, LegroRS. Oral contraceptive use by teenage women does not affect body composition. Obstet Gynecol100:235–239, 2002.
59.
MastorakosG, KoliopoulosC, CreatsasG.Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril77:919–927, 2002.
60.
RandevaHS, LewandowskiKC, DrzewoskiJ, Brooke-WavellK, O'CallaghanC, CzupryniakL, HillhouseEW, PrelevicGM. Exercise decreases plasma total homocysteinc in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab87:4496–4501, 2002.
61.
ClarkAM, LedgerW, GalletlyC, TomlinsonL, BlaneyF, WangX, NormanRJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod10:2705–2712, 1995.
62.
ApterD.How possible is the prevention of polycystic ovary syndrome development in adolescent patients with early onset of hyperandrogenism. J Endocrinol Invest21:613–617, 1998.
63.
MoranLJ, NoakesM, CliftonPM, TomlinsonL, NormanRJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab88:812–819, 2003.
64.
ChouKH, von Eye CorletaH, CappE, SpritzerPM. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res35:86–91, 2003.
65.
KazerooniT, Dehghan-KooshkghaziM.Effects of metformin therapy on hyperandrogenism in women with polycystic ovary syndrome. Gynecol Endocrinol17:51–56, 2003.
66.
MoghettiP, CastelloR, NegriC, TosiF, PerroneF, CaputoM, ZanolinE, MuggeoM.Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab85:139–146, 2000.
67.
Morin-PapunenL, VauhkonenI, KoivunenR, RuokonenA, MartikainenH, TapanainenJS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab88:148–156, 2003.
68.
VandermolenDT, RattsVS, EvansWS, StovallDW, KaumaSW, NestlerJE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril75:310–315, 2001.
69.
ArslanianSA, LewyV, DanadianK, SaadR.Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab87:1555–1559, 2002.
70.
GlueckCJ, WangP, FontaineR, TracyT, Sieve-SmithL.Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health29:160–169, 2001.
71.
IbáñezL, VallsC, PotauN, MarcosMV, de ZegherF.Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab85:3526–3530, 2000.
72.
IbáñezL, de ZegherF.Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab88:4720–4724, 2003.
73.
FreemarkM, BurseyD.The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics107(4):E55, 2001.
74.
LoverroG, LorussoF, De PergolaG, NicolardiV, MeiL, SelvaggiL.Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol16:217–224, 2002.
75.
Morin-PapunenL, RautioK, RuokonenA, HedbergP, PuukkaM, TapanainenJS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab88:4649–4654, 2003.
76.
GhazeeriG, KuttehWH, Bryer-AshM, HaasD, KeRW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril79:562–566, 2003.
77.
RomualdiD, GuidoM, CiampelliM, GiulianiM, LeoniF, PerriC, LanzoneA.Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod18:1210–1218, 2003.
78.
GlueckCJ, MoreiraA, GoldenbergN, SieveL, WangP.Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod18:1618–1625, 2003.
79.
NestlerJE, JakubowiczDJ, IuornoMJ. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol Metab 13(Suppl 5):1295–1298, 2000.
80.
HouJ, YuJ, WeiM.Study on treatment of hyperandrogenism and hyperinsulinism in polycystic ovary syndrome with Chinese herbal formula “tiangui fang.” Zhongguo Zhong Xi Yi Jie He Za Zhi 20:589–592, 2000.
AndersonRA, ChengN, BrydenNA, PolanskyMM, ChengN, ChiJ, FengJ.Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes46:1786–1791, 1997.
83.
DulebaAJ, BanaszewskaB, SpaczynskiRZ, PawelczykL.Success of laparoscopic ovarian wedge resection is related to obesity, lipid profile, and insulin levels. Fertil Steril79:1008–1014, 2003.
84.
YildirimM, NoyanV, Bulent TirasM, YildizA, GunerH.Ovarian wedge resection by minilaparatomy in infertile patients with polycystic ovarian syndrome: a new technique. Eur J Obstet Gynecol Reprod Biol107:85–87, 2003.
